We further validated this approach by analysing a 180 bp region from the promoter of the SEPT9 gene, one of the few FDA-approved methylation markers for colorectal cancer, and demonstrated the ability of SERS to distinguish hypermethylation. This evidence concerns the gene SEPTIN9 and colorectal cancer.